Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Cognition Therapeutics Inc

Healthcare US CGTX

1.29USD
-0.07(5.15%)

Last update at 2026-06-05T20:23:00Z

Day Range

1.221.33
LowHigh

52 Week Range

0.223.83
LowHigh

Fundamentals

  • Previous Close 1.36
  • Market Cap100.08M
  • Volume1088997
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-47.76300M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.32

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -23.48700M -33.97100M -25.78800M -21.39700M -11.71600M
Minority interest - - - - -
Net income -23.48700M -33.97100M -25.78800M 0.76M -10.28500M
Selling general administrative 10.61M 12.29M 13.53M 13.23M 10.03M
Selling and marketing expenses - - 0.25M - -
Gross profit -0.22800M -0.26600M -0.25200M - -
Reconciled depreciation 0.23M 0.27M 0.25M 0.23M 0.09M
Ebit -48.02700M -33.94600M -25.76100M -43.55100M -28.59800M
Ebitda -47.79900M -33.68000M -25.50900M -21.13400M -13.38200M
Depreciation and amortization 0.23M 0.27M 0.25M 22.42M 15.22M
Non operating income net other - - - -0.03500M -
Operating income -47.79900M -53.96600M -50.72400M -43.55100M -28.59800M
Other operating expenses 47.80M 53.97M 50.72M 21.33M 11.15M
Interest expense 0.01M 0.03M 0.03M 0.03M 0.89M
Tax provision - - - - -
Interest income - - - - -
Net interest income -0.01300M -0.02500M -0.02800M -0.02800M -0.89300M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - -22.15400M -1.43100M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 47.80M 53.97M 50.72M 21.33M 11.15M
Cost of revenue 0.23M 0.27M 0.25M - -
Total other income expense net 24.31M 20.00M 24.94M 22.15M 16.88M
Discontinued operations - - - - -
Net income from continuing ops -23.48700M -33.97100M -22.82900M -43.61400M -11.71600M
Net income applicable to common shares - - - -21.39700M -16.24800M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 48.39M 30.23M 35.16M 50.42M 59.14M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.26M 1.86M 3.02M 2.41M 0.01M
Total liab 14.12M 11.48M 10.69M 10.18M 7.86M
Total stockholder equity 34.27M 18.75M 24.47M 40.25M 51.27M
Deferred long term liab - - - - -
Other current liab 11.99M 7.62M 4.60M 2.09M 3.70M
Common stock 0.09M 0.06M 0.03M 0.03M 0.02M
Capital stock 0.09M 0.06M 0.03M 0.03M 0.02M
Retained earnings -198.64700M -175.16000M -141.18900M -115.40100M -94.00400M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.00000M - -
Cash 36.81M 25.01M 29.92M 41.56M 54.72M
Cash and equivalents - - - - -
Total current liabilities 13.92M 11.14M 10.17M 7.79M 7.86M
Current deferred revenue 0.37M 1.07M 1.70M 1.70M -
Net debt -36.17200M -24.19500M -29.74800M -40.08400M -54.72100M
Short term debt 0.44M 0.47M 0.17M 0.78M -
Short long term debt 0.31M 0.28M 0.54M 0.63M -
Short long term debt total 0.64M 0.81M 0.17M 1.48M -
Other stockholder equity 232.83M 193.85M 165.83M 155.82M 86.32M
Property plant equipment - - - 0.23M 0.14M
Total current assets 47.99M 29.55M 34.22M 47.65M 58.99M
Long term investments - - - - -
Net tangible assets - - - 40.25M 51.27M
Short term investments - - - - -
Net receivables 9.92M 2.69M 1.28M 3.67M 2.27M
Long term debt - - - - -
Inventory - - - - 1.99M
Accounts payable 1.12M 1.98M 3.69M 3.22M 4.17M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - -0.19500M -0.19900M -0.19800M
Additional paid in capital - - - - -
Common stock total equity - - - 0.03M -
Preferred stock total equity - - - - -
Retained earnings total equity - - - -115.40100M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - -0.00000M 1.73M -
Deferred long term asset charges - - - - -
Non current assets total 0.40M 0.68M 0.94M 2.78M 0.14M
Capital lease obligations 0.33M 0.54M 0.69M 0.84M -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.00400M -0.12700M -0.17100M -0.02700M
Change to liabilities - - - -0.74900M 2.17M
Total cashflows from investing activities 0.00900M -0.00400M -0.14700M -0.17100M -0.02700M
Net borrowings -0.35300M -0.73900M -0.81100M -1.39600M -0.26800M
Total cash from financing activities 36.57M 23.57M 4.52M 5.55M 53.20M
Change to operating activities - - - - 0.56M
Net income -23.48700M -33.97100M -25.78800M -21.39700M -11.71600M
Change in cash 11.99M -4.91300M -11.64000M -13.15900M 49.53M
Begin period cash flow 25.01M 29.92M 41.56M 54.72M 5.19M
End period cash flow 37.00M 25.01M 29.92M 41.56M 54.72M
Total cash from operating activities -24.58800M -28.47400M -16.01800M -18.53300M -3.63100M
Issuance of capital stock 37.02M 24.35M 8.04M 5.32M 44.22M
Depreciation 0.23M 0.27M 0.25M 0.23M 0.09M
Other cashflows from investing activities 0.00900M -0.00400M - - -
Dividends paid - - - - -
Change to inventory - - -2.44000M - -
Change to account receivables -7.23700M -1.40500M 2.39M - 0.12M
Sale purchase of stock - - - 6.94M -
Other cashflows from financing activities -0.16400M -0.04600M -0.14700M 1.62M 9.25M
Change to netincome - - - 3.57M 4.77M
Capital expenditures 0.00000M 0.00400M 0.15M 0.17M 0.03M
Change receivables - - - 0.47M -
Cash flows other operating - - - -0.50900M -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -13.15800M -
Change in working capital -3.45700M 1.29M 4.85M -0.94300M 2.84M
Stock based compensation 2.09M 3.75M 4.35M 3.57M 5.18M
Other non cash items 0.04M 0.20M 0.32M - 0.38M
Free cash flow -24.58800M -28.47800M -16.16500M -18.70400M -3.65800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
CGTX
Cognition Therapeutics Inc		 -0.07 5.15% 1.29 - - - 2.92 -0.4433
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.

Cognition Therapeutics Inc

2500 Westchester Ave., Purchase, NY, United States, 10577

Key Executives

Name Title Year Born
Ms. Lisa Ricciardi CEO, Pres & Director 1960
Dr. Anthony O. Caggiano M.D., Ph.D. Chief Medical Officer and Head of R&D NA
Mr. Andrew J. Einhorn CPA Interim Chief Financial Officer 1960
Ms. Lisa Ricciardi CEO, President & Director 1960
Mr. John Brendan Doyle Chief Financial Officer 1977
Dr. Steven A. Weissman Ph.D. VP & Head of CMC NA
Dr. Anthony O. Caggiano M.D., Ph.D. Chief Medical Officer and Head of R&D 1970
Ms. Anita Cornet Head of Quality NA
Mr. Bobby Horn Corporate Controller NA
Dr. Anthony O. Caggiano M.D., Ph.D. Chief Medical Officer 1970

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions